MedTrace Logo

Prebiotics in Rectal Cancer

NCT05516641 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-03-31

No results posted yet for this study

Summary

A significant racial disparity in the incidence and mortality of CRC exists in the U.S. with African Americans having CRC incidence and mortality rates that are 20% and 40% higher than the general U.S. population. It has been demonstrated that the gut microbiome impacts tumor development and progression through multiple mechanisms, including impacting the tumoral immune response. However, it is unknown if microbiome modulating treatment can have an impact on CRC outcomes.

Conditions

Interventions

DIETARY_SUPPLEMENT

Soluble Corn Fiber

once daily additive to diet

DIETARY_SUPPLEMENT

Maltodextrin

once daily additive to diet

Sponsors & Collaborators

  • Ochsner Health System

    lead OTHER

Principal Investigators

  • Li Li, MD, PhD · Ochsner

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2023-12-31
Completion
2024-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05516641 on ClinicalTrials.gov